Animal model pharmacokinetics and pharmacodynamics: a critical review.

Animals have been extensively used in the evaluation of antimicrobials. The value of animals in the pharmacokinetic and pharmacodynamic characterization of antimicrobials is critically reviewed. Animal studies have demonstrated that the pharmacokinetic/pharmacodynamic (PK/PD) target determining efficacy can vary for different classes of antimicrobials. However, the magnitude of the target required for bacteriological efficacy is relatively similar for various sites of infection, various pathogens and various drugs within the same class, provided free drug levels are used.

[1]  W. Craig,et al.  Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  W. Craig,et al.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. , 1989, The Journal of infectious diseases.

[3]  W. Craig,et al.  Evidence for a slow elimination phase for penicillin G. , 1988, The Journal of infectious diseases.

[4]  A. Dalhoff,et al.  Pharmacokinetics of Fluoroquinolones in Experimental Animals , 1998 .

[5]  J. Pechère,et al.  Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia. , 1987, The Journal of antimicrobial chemotherapy.

[6]  H. Neu,et al.  Expanding indications for the new macrolides, azalides, and streptogramins. , 1997 .

[7]  W. Craig,et al.  In Vivo Activities of Amoxicillin and Amoxicillin-Clavulanate against Streptococcus pneumoniae: Application to Breakpoint Determinations , 1998, Antimicrobial Agents and Chemotherapy.

[8]  G. Rolinson,et al.  Effect of protein binding on antibiotic activity in vivo. , 1983, The Journal of antimicrobial chemotherapy.

[9]  W. Craig,et al.  Role of antimicrobial pharmacokinetics and pharmacodynamics in surgical prophylaxis. , 1991, Reviews of infectious diseases.

[10]  N. White,et al.  A prospective clinical and bacteriologic study of inguinal buboes in Thai men. , 1996, Clinical Infectious Diseases.

[11]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[12]  W. Craig,et al.  Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[13]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[14]  M. Sande,et al.  Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. , 1988, The Journal of infectious diseases.

[15]  W. Craig,et al.  Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. , 1991, The Journal of antimicrobial chemotherapy.

[16]  A. Karim.  The pharmacokinetics of Norpace. , 1975, Angiology.